IRIS

Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 71
Titolo Tipologia Data di pubblicazione Autore(i) File
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 8.02 Comunicazioni a Convegni o Seminari 2020 Servetto, A; Kollipara, R; Formisano, L; Lin, A; Lee, Km; Sudhan, Dr; Hanker, Ab; Chatterjee, S; Guerrero-Zotano, A; Gonzalez-Ericsson, ; Mendiratta, S; James, N; Kittler, R; Arteaga, Cl
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 1.1 Articolo in rivista 2020 Foschini, F.; Napolitano, F.; Servetto, A.; Marciano, R.; Mozzillo, E.; Carratu, A. C.; Santaniello, A.; De Placido, P.; Cascetta, P.; Butturini, G.; Frigerio, I.; Regi, P.; Silvestris, N.; Delcuratolo, S.; Vasile, E.; Vivaldi, C.; Bianco, C.; De Placido, S.; Formisano, L.; Bianco, R.
Mechanisms of resistance to mTOR inhibitors 1.1 Articolo in rivista 2020 Formisano, L.; Napolitano, F.; Rosa, R.; D'Amato, V.; Servetto, A.; Marciano, R.; De Placido, P.; Bianco, C.; Bianco, R.
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 1.1 Articolo in rivista 2020 Arpino, G.; De Angelis, C.; De Placido, P.; Pietroluongo, E.; Formisano, L.; Bianco, R.; Fiore, G.; Montella, E.; Forestieri, V.; Lauria, R.; Cardalesi, C.; Vozzella, E. A.; Iervolino, A.; Giuliano, M.; De Placido, S.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 1.1 Articolo in rivista 2020 Ciciola, Paola; Cascetta, Priscilla; Bianco, Cataldo; Formisano, Luigi; Bianco, Roberto
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 1.1 Articolo in rivista 2020 Sudhan, Dhivya R; Guerrero-Zotano, Angel; Won, Helen; González Ericsson, Paula; Servetto, Alberto; Huerta-Rosario, Mariela; Ye, Dan; Lee, Kyung-Min; Formisano, Luigi; Guo, Yan; Liu, Qi; Kinch, Lisa N; Red Brewer, Monica; Dugger, Teresa; Koch, James; Wick, Michael J; Cutler, Richard E; Lalani, Alshad S; Bryce, Richard; Auerbach, Alan; Hanker, Ariella B; Arteaga, Carlos L
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 1.1 Articolo in rivista 2020 Lee, K. -M.; Guerrero-Zotano, A. L.; Servetto, A.; Sudhan, D. R.; Lin, C. -C.; Formisano, L.; Jansen, V. M.; Gonzalez-Ericsson, P.; Sanders, M. E.; Stricker, T. P.; Raj, G.; Dean, K. M.; Fiolka, R.; Cantley, L. C.; Hanker, A. B.; Arteaga, C. L.
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 1.1 Articolo in rivista 2020 Belli, S.; Esposito, D.; Servetto, A.; Pesapane, A.; Formisano, L.; Bianco, R.
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. 1.1 Articolo in rivista 2019 Croessmann, S; Formisano, L; Kinch, Ln; Gonzalez-Ericsson, Pi; Sudhan, Dr; Nagy, Rj; Mathew, A; Bernicker, Eh; Cristofanilli, M; He, J; Cutler RE, Jr; Lalani, As; Miller, Va; Lanman, Rb; Grishin, Nv; Arteaga, Cl.
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 1.7 Commento, erratum, replica e simili 2019 Guerrero-Zotano, A. L.; Stricker, T. P.; Formisano, L.; Hutchinson, K. E.; Stover, D. G.; Lee, K. -M.; Schwarz, L. J.; Giltnane, J. M.; Estrada, M. V.; Jansen, V. M.; Servetto, A.; Gavila, J. J.; Perez-Fidalgo, A.; Lluch, A.; Llombart-Cussac, A.; Bayar, M. A.; Michiels, S.; Andre, F.; Arnedos, M.; Guillem, V.; Ruiz-Simon, A.; Arteaga, C. L.
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 1.1 Articolo in rivista 2019 Formisano, L; Lu, Y; Servetto, A; Hanker, Ab; Jansen, Vm; Bauer, Ja; Sudhan, Dr; Guerrero-Zotano, Al; Croessmann, S; Guo, Y; Ericsson, Pg; Lee, Km; Nixon, Mj; Schwarz, Lj; Sanders, Me; Dugger, Tc; Cruz, Mr; Behdad, A; Cristofanilli, M; Bardia, A; O'Shaughnessy, J; Nagy, Rj; Lanman, Rb; Solovieff, N; He, W; Miller, M; Su, F; Shyr, Y; Mayer, Ia; Balko, Jm; Arteaga, Cl.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 1.1 Articolo in rivista 2019 Nixon, M. J.; Formisano, L.; Mayer, I. A.; Estrada, M. V.; Gonzalez-Ericsson, P. I.; Isakoff, S. J.; Forero-Torres, A.; Won, H.; Sanders, M. E.; Solit, D. B.; Berger, M. F.; Cantley, L. C.; Winer, E. P.; Arteaga, C. L.; Balko, J. M.
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 1.1 Articolo in rivista 2019 Santaniello, A.; Napolitano, F.; Servetto, A.; De Placido, P.; Silvestris, N.; Bianco, C.; Formisano, L.; Bianco, R.
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 1.1 Articolo in rivista 2019 Napolitano, F; Formisano, L; Giardino, A; Girelli, R; Servetto, A; Santaniello, A; Foschini, F; Marciano, R; Mozzillo, E; Carratù, Ac; Cascetta, P; De Placido, P; De Placido, S; Bianco, R.
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 1.8 Articolo in rassegna (review) 2019 Buonerba, C.; Iaccarino, S.; Dolce, P.; Pagliuca, M.; Izzo, M.; Scafuri, L.; Costabile, F.; Riccio, V.; Ribera, D.; Mucci, Brigitta; Carrano, S.; Picozzi, F.; Bosso, D.; Formisano, L.; Bianco, R.; De Placido, S.; Di Lorenzo, G.
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. 1.1 Articolo in rivista 2019 Sudhan, Dr; Schwarz, Lj; Guerrero-Zotano, A; Formisano, L; Nixon, Mj; Croessmann, S; González Ericsson, Pi; Sanders, M; Balko, Jm1; Avogadri-Connors, F; Cutler, Re; Lalani, As; Bryce, R; Auerbach, A; Arteaga, Cl.
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 1.1 Articolo in rivista 2019 Formisano, L; Drago, Jz; Juric, D; Niemierko, A; Servetto, A; Wander, Sa; Spring, Lm; Vidula, N; Younger, J; Peppercorn, J; Yuen, M; Malvarosa, G; Sgroi, D; Isakoff, Sj; Moy, B; Ellisen, Lw; Iafrate, Aj; Arteaga, Cl; Bardia, A
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 1.1 Articolo in rivista 2018 Schettini, F; De Santo, I; Rea, Cg; De Placido, P; Formisano, L; Giuliano, M; Arpino, G; De Laurentiis, M; Puglisi, F; De Placido, S; Del Mastro, L.
From biology to therapy: Improvements of therapeutic options in Lung cancer 1.2 Recensione in rivista 2018 Formisano, Luigi; Jansen, Valerie M; Marciano, Roberta; Bianco, Roberto
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 1.1 Articolo in rivista 2018 Luo1, Na; Formisano, Luigi; Gonzalez-Ericsson, Paula I.; Sanchez, Violeta; Dean, Phillip T.; Opalenik, Susan R.; Sanders, Melina E.; Cook, Rebecca S.; Arteaga, Carlos L.; Johnson, Douglas B.; Balko, Justin M.
Mostrati risultati da 21 a 40 di 71
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile